Novartis: spartalizumab fails clinical trial
(CercleFinance.com) - Novartis announces that its COMBI-i Phase III study, evaluating the investigational immunotherapy spartalizumab (PDR001), in combination with the targeted therapies Tafinlar and Mekinist, has failed to meet its primary endpoint of progression-free survival.
"The trial was conducted among untreated patients with unresectable (Stage IIIC) or metastatic (Stage IV) BRAF V600 mutation-positive cutaneous melanoma, compared to Tafinlar + Mekinist alone," the Swiss pharmaceutical group said.
Novartis will continue to study the data from the study, which is expected to be presented at a future medical congress. The development program for spartalizumab will continue, with studies of combinations with other anti-cancer agents.
Copyright (c) 2020 CercleFinance.com. All rights reserved.
"The trial was conducted among untreated patients with unresectable (Stage IIIC) or metastatic (Stage IV) BRAF V600 mutation-positive cutaneous melanoma, compared to Tafinlar + Mekinist alone," the Swiss pharmaceutical group said.
Novartis will continue to study the data from the study, which is expected to be presented at a future medical congress. The development program for spartalizumab will continue, with studies of combinations with other anti-cancer agents.
Copyright (c) 2020 CercleFinance.com. All rights reserved.